Company
Headquarters: Exton, PA, United States
Employees: 23
CEO: Dr. Purnanand Duddu Sarma
$769.2 Million
USD as of July 1, 2025
| Company | Market Cap (USD) | 
|---|---|
| Novo Nordisk | $309.91 B | 
| Vertex Pharmaceuticals Incorporated | $117.36 B | 
| CSL Limited | $95.75 B | 
| Regeneron Pharmaceuticals, Inc. | $59.14 B | 
| Marinomed Biotech AG | $58.56 B | 
| Company | Market Cap (USD) | 
|---|---|
| Lilly | $699.59 B | 
| Johnson & Johnson | $374.29 B | 
| AbbVie | $336.94 B | 
| Novo Nordisk | $309.91 B | 
| UnitedHealth Group | $279.90 B | 
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Immunome, Inc. has the following listings and related stock indices.
Stock: NASDAQ: IMNM wb_incandescent